ClinicalTrials.gg
CompletedNCT00035620Updated Feb 26, 2010

Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

A Phase 2 interventional study of pegfilgrastim and filgrastim in Sarcoma and Neutropenia, sponsored by Amgen. Completed. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2010-02-26.

Sponsored by Amgen · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
Up to 21 Years
Sex
All
01

Study summary

Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced. Neutrophils are a type of white blood cells that fight infection and are produced in the bone marrow. If the neutrophil count becomes too low due to chemotherapy, a potentially serious condition called neutropenia occurs. Neutropenia is serious because it can affect the body's ability to protect against many types of infections. Pegfilgrastim is an investigational drug being evaluated for its potential ability to increase the number of neutrophils. The purpose of this study is to determine the safety and effectiveness of pegfilgrastim in preventing neutropenia following chemotherapy in pediatric patients up through the age of 21 with sarcoma.

02

Conditions studied

  • Sarcoma
  • Neutropenia

Keywords

  • Bone cancer
  • Sarcoma
  • Neutropenia
  • Chemotherapy
03

In context

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

This study's enrollment of 44 is close to the median of 41 across 1,254 interventional studies indexed under Sarcoma.

Browse Sarcoma studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Sarcoma * No previous chemotherapy or radiotherapy * Patients who will be receiving chemotherapy consisting of Vincristine, Doxorubicin, Cyclophosphamide, Etoposide, Ifosfamide, and Mesna
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Filgrastim

    Filgrastim

    Drug: filgrastim

  • Experimental
    Pegfilgrastim

    Pegfilgrastim

    Drug: pegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. Duration of severe neutropenia in chemotherapy in cycles 1 and 3

    Time frame: cycles 1 and 3

  2. Time to ANC recovery to greater than or equal to 0.5 x 10^9/L in cycles 1 and 3

    Time frame: cycles 1 and 3

Secondary outcomes

  1. Pharmacokinetic profile in chemotherapy cycles 1 and 3

    Time frame: cycles 1 and 3

  2. Incidence of adverse events across all cycles of chemotherapy

    Time frame: all cycles

  3. Overall rates of febrile neutropenia

    Time frame: all cycles

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2000, a primary completion of Jan 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2002
First posted
May 6, 2002
Start
Apr 2000
Primary completionActual
Jan 2007
CompletionActual
Apr 2007
Last update
Feb 26, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00035620
Lead sponsor
Amgen
First posted
May 6, 2002
Start date
Apr 2000
Primary completion
Jan 2007
Completion
Apr 2007
Last update
Feb 26, 2010

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion